Redhill Biopharma (TASE:RDHL), (NASDAQ:RDHL) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of a variety of diseases, including gastrointestinal and inflammatory disorders and cancer. With a deep commitment to innovation, Redhill conducts research and clinical development programs to bring new therapies to market that aim to improve patient outcomes. The company's portfolio spans both early and late-stage projects, targeting unmet medical needs with the potential to offer better efficacy or safety profiles than existing treatments. Redhill's objectives are centered on advancing its pipeline through clinical trials, securing partnerships for broader global reach, and ultimately transforming promising scientific discoveries into accessible medical solutions for patients worldwide.